Changes in lung function and exercise capacity are strong predictors of mortality in patients with IPF receiving antifibrotic therapy.

ABSTRACT:

Background

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial pneumonia with poor prognosis. This study evaluated whether monitoring changes in lung function and exercise capacity during antifibrotic therapy offers superior prognostic value compared with baseline clinical parameters in IPF.

Methods

We retrospectively analyzed patients with IPF enrolled with the Korean IPF cohort registry between June 2016 and August 2021. Prognostic factors for mortality were assessed using Cox proportional hazards models and receiver operating characteristic (ROC) curve analysis.

Results

Among 1,229 patients (mean age 68.3 years; 82.8% male), 88.0% received antifibrotic therapy. During a median follow-up of 41.0 months, 37.9% of the treated patients died. Multiva

SUBMITTER: Oh JH 

PROVIDER: S-EPMC12537395 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature